Research Shows HRT Improves the Effectiveness of GLP1s After Menopause
The Connection Between HRT & GLP1 Weight Loss
Can HRT make GLP1 weight loss medications work better for women after menopause? Two recent studies from Mayo Clinic researchers suggest that women using hormone therapy may lose more weight on semaglutide, the active ingredient in Wegovy and Ozempic, than women who are not. The findings are early and observational, but they have sparked a great deal of interest among women who have struggled with midlife weight gain.
At our Austin, TX practice, renowned menopause expert Ruthie Harper, MD has spent years helping women restore hormonal balance and reclaim their energy. We are watching this research closely because it brings together two of the most common concerns women bring to us in midlife: bothersome menopause symptoms and stubborn weight gain.
The Difficulty of Menopause Weight Loss
Many women notice that their bodies begin to change in their forties and fifties, even when their eating and exercise habits have not. Clothes fit differently, and weight that once settled on the hips and thighs begins to collect around the waist. Familiar strategies that worked a decade earlier often stop producing results, which can be discouraging.
Several factors are at work. Aging itself gradually reduces muscle mass and slows metabolism, while sleep disruption, stress and changes in activity levels add to the challenge. Declining estrogen also appears to shift where the body stores fat, favoring the abdomen. No single hormone explains every change, which is why menopause weight loss usually calls for a broader approach than willpower alone.
Long-term research supports this picture. The Study of Women’s Health Across the Nation, which has followed thousands of women through midlife, found that fat mass tends to rise and lean muscle tends to decline during the menopause transition, with the fastest changes occurring in the years surrounding a woman’s final period.
Researchers are now asking whether a woman’s reproductive stage, and whether she uses hormone therapy, might influence how her body responds to weight loss medications. That question matters because GLP1 drugs were largely studied in mixed groups of men and women, without close attention to menopause.
Top Austin, TX hormone therapy expert Dr. Ruthie Harper evaluates menopause symptoms and weight concerns as separate issues that deserve their own assessments, even when they show up at the same time. This allows her to recommend HRT, weight management support or both based on what each woman truly needs.
Early HRT and GLP1 Research
The first signal came from a study published in the journal Menopause in 2024. Mayo Clinic researchers reviewed the medical records of 106 postmenopausal women with overweight or obesity who had taken semaglutide for at least three months. Sixteen of them were using menopause hormone therapy, and 90 were not.
The women using HRT lost more weight at every checkpoint. After 12 months, they had lost an average of about 16 percent of their total body weight, compared with about 12 percent among women not using hormones. The difference held up after the researchers adjusted for other factors that might affect weight.
Still, this was a small retrospective study that looked back at existing records rather than randomly assigning women to add HRT. The hormone therapy group included only 16 women, and the researchers noted that women who use HRT may differ in other ways, such as having better access to care or healthier daily habits. The authors called for larger studies to confirm the results.
For women considering treatment, the takeaway is that the 2024 findings justify further research rather than promising extra pounds lost for any individual. In our Austin, TX office, Ruthie Harper, MD shares studies like this one in plain language so patients can make informed choices about HRT and weight management.
Recent Evidence on HRT & GLP1 Weight Loss
A much larger study followed in October 2026. On October 20, The Menopause Society announced findings presented at its annual meeting in San Diego by Dr. Regina Castaneda of Mayo Clinic Florida. The research team reviewed records from nearly 2,400 women taking semaglutide and nearly 1,500 women taking tirzepatide, the active ingredient in Mounjaro and Zepbound. All of the women were older than 45 and had a body mass index above 27.
Among women taking semaglutide, HRT use was associated with significantly greater weight loss that was sustained over time. Women on tirzepatide who used hormone therapy also lost more weight early on, but by the end of the study the difference between the groups was no longer statistically significant. The researchers noted that the hormone therapy effect appeared stronger with semaglutide, a pattern they believe deserves closer study.
These results come from a conference presentation described by the society, and they have not yet appeared in a peer-reviewed journal. Like the earlier study, the design was retrospective and observational, which means it can show an association but cannot prove that HRT caused the added weight loss. Dr. Castaneda herself cautioned that it is too early to draw firm conclusions.
Renowned Austin, TX menopause expert Ruthie Harper, MD keeps current with research presented by The Menopause Society, and she uses the latest evidence to guide the personalized hormone and weight management plans she creates for her patients.
Wegovy, Ozempic & Hormone Therapy
Because both studies focused largely on semaglutide, women taking Wegovy or Ozempic understandably want to know what the findings mean for them. At this point the research cannot recommend a specific combination of HRT and a GLP1, and no clinical trial has tested adding hormone therapy to improve results.
Scientists have proposed one possible explanation. Laboratory and animal research suggests that estrogen and GLP1 signaling may work together in parts of the brain and body that regulate appetite and energy use. HRT may also ease hot flashes and night sweats, which can improve sleep and make it easier to stay active. These ideas remain theories, and the studies so far cannot establish whether HRT itself was responsible for the difference.
It is equally important to understand what these findings do not mean. GLP1 medications work well without hormone therapy, and HRT is not required to benefit from Wegovy. The Menopause Society has stated clearly that weight loss alone is not a reason to prescribe menopause hormone therapy, and its 2022 position statement bases HRT decisions on symptoms, age, time since menopause and individual health risks.
What we do at our Austin, TX menopause practice reflects that guidance. Hormone therapy expert Dr. Ruthie Harper prescribes HRT only when it is medically appropriate for a woman’s symptoms and health history, never solely to boost GLP1 weight loss.
HRT & GLP1 Doctor| Austin, TX
If you are dealing with menopause symptoms and weight gain at the same time, you deserve an evaluation that looks at both. Dr. Ruthie Harper will review your symptoms, weight history, lab work, current medications and personal goals before recommending a plan. For some women, relieving hot flashes and improving sleep first makes healthy eating and regular exercise far easier to maintain.
Depending on your circumstances, the right choice may be HRT, a GLP1 medication, both or neither. Weight loss on any medication tends to be gradual, and regular follow-up visits allow Dr. Harper to monitor your progress, manage side effects and adjust treatment as needed. Eating enough protein, staying active and adding strength training help protect your muscle and keep your results lasting.
To explore a personalized plan for menopause and weight management, schedule an appointment with renowned menopause expert Ruthie Harper, MD in Austin, TX.
